MGC018 With or Without MGA012 in Advanced Solid Tumors

Inclusion Criteria: * Tissue specimen available for retrospective analysis of B7-H3 and PD-L1 expression. * Eastern Cooperative Oncology Group performance status of ≤2 * Life expectancy ≥ 12 weeks for dose escalation phase and ≥ 24 weeks for cohort expansion phase * Measurable disease. Prostate cancer patients with bone only disease are eligible. * Acceptable laboratory parameters and adequate organ reserve. * Dose Escalation Phase: Patients with histologically proven, unresectable, locally advanced or metastatic solid tumors for whom no therapy with demonstrated clinical benefit is available. Module A Cohort Expansion: * mCRPC that has progressed with one prior line of chemotherapy for metastatic disease and no more than two prior lines of anti-hormonal therapy. * NSCLC: metastatic disease after standard cytotoxic, targeted, and biologic or checkpoint inhibitor therapy. No more than 2 prior lines of chemotherapy. * TNBC: Locally advance or metastatic disease that has progressed following at least one systemic therapy. * SCCHN that has progressed during or following at least one systemic therapy for metastatic or recurrent unresectable disease. No more than 2 prior lines of chemotherapy. * Melanoma that has progressed during or following at least one systemic treatment for unresectable locally advanced or metastatic disease. Patients who are intolerant of or refused standard therapy are eligible. Exclusion Criteria: * Patients with history of prior central nervous system…